Skin Tags: What Labs to Get and Clinical Next Steps

What a skin tag is, and what it is not

A skin tag, medically called an acrochordon or fibroepithelial polyp, is a soft, flesh-colored, stalk-based growth made of a fibrovascular core covered by ordinary epidermis. Most measure 1 to 5 mm. It is a distinct entity from a wart (caused by HPV, usually rougher-surfaced), a seborrheic keratosis (a stuck-on, waxy growth), or a mole (a pigmented nevus). Skin tags form almost exclusively in friction zones: the neck, armpits, eyelids, groin, and under the breasts.

They are extremely common in clinical samples. A case-control study in the International Journal of Dermatology identified acrochordons in 46% of the population it studied, with prevalence rising sharply after age 40 Rasi et al., 2007. That figure describes the study's sample, not a validated general-population estimate, but it is consistent with how common the finding is in routine dermatology and primary care visits.

Skin tags carry no malignant potential. No case series has documented a true acrochordon transforming into melanoma or squamous cell carcinoma. Their clinical relevance is not the growth itself. It is what a cluster of them may indicate about metabolic health.

Why skin tags track with insulin resistance

The most reproducible finding in this literature is the association between multiple skin tags and hyperinsulinemia. Insulin and insulin-like growth factor 1 (IGF-1) bind receptors on keratinocytes and dermal fibroblasts and stimulate their proliferation. When insulin is chronically elevated, as happens with insulin resistance, cell turnover in friction-prone skin accelerates, producing visible outgrowths.

Tamega and colleagues compared 98 patients with skin tags to 103 controls and found significantly higher HOMA-IR (a calculated index of insulin resistance) and fasting insulin in the skin tag group Tamega et al., 2010. Rasi and colleagues reported that skin tags remained an independent marker of impaired carbohydrate metabolism after adjusting for BMI Rasi et al., 2007. Kahana and colleagues published one of the earliest controlled studies describing skin tags as a cutaneous marker for diabetes mellitus, in 1987 Kahana et al., 1987.

The American Diabetes Association's 2024 Standards of Care state that certain dermatologic findings, including acanthosis nigricans and skin tags, should prompt clinicians to consider screening for prediabetes and type 2 diabetes ADA Standards of Care, 2024. This is a guideline-level statement, not a claim that a skin tag itself is diagnostic.

Crook's work in the Journal of Clinical Pathology argues that a visible skin tag functions as a low-cost clinical clue that should lower the threshold for metabolic workup, particularly when tags appear in clusters rather than singly Crook, 2000. That paper also links skin tags to an unfavorable lipid pattern (elevated triglycerides, low HDL), a finding a separate study by Gorpelioglu and colleagues supports, reporting significantly higher fasting triglycerides in patients with skin tags compared with controls Gorpelioglu et al., 2009. The exact magnitude of that triglyceride difference varies by study population, so treat any single study's numeric mean as illustrative rather than a number to apply to an individual patient.

Skin tags are benign fibrovascular growths with no malignant potential, but case-control studies consistently associate multiple skin tags with elevated fasting insulin and HOMA-IR independent of BMI. That association does not make a skin tag a diagnostic test for diabetes. It means a cluster of tags is a reasonable, evidence-supported trigger for a fasting glucose, HbA1c, and fasting insulin panel, consistent with ADA guidance on dermatologic clues to prediabetes risk.

What labs to request

If you have multiple skin tags, particularly five or more, a targeted metabolic panel can identify a driver before it produces symptoms. Ask your clinician to order the following.

Fasting glucose. A value of 100 to 125 mg/dL meets criteria for impaired fasting glucose (prediabetes). A value of 126 mg/dL or higher on two separate occasions meets ADA criteria for diabetes ADA Standards of Care, 2024.

HbA1c. This reflects average blood sugar over roughly 2 to 3 months. A result of 5.7% to 6.4% is prediabetic; 6.5% or above is diabetic. Tamega and colleagues found mean HbA1c was measurably higher in the skin tag group than in controls, though the exact study means should not be read as population targets Tamega et al., 2010.

Fasting insulin. Standard metabolic panels do not include this by default; you need to request it. Reference ranges vary by lab, but the HOMA-IR calculation (fasting insulin x fasting glucose / 405) gives a more interpretable single number. A HOMA-IR above roughly 2.5 is generally considered consistent with insulin resistance, though thresholds vary across labs and populations.

Lipid panel. Look at triglycerides, HDL, and the triglyceride-to-HDL ratio, which multiple studies link to skin tag presence Crook, 2000; Gorpelioglu et al., 2009.

Consider adding: a thyroid panel (TSH, free T4) and, in women with irregular periods, acne, or hirsutism, total and free testosterone, DHEA-S, and SHBG to screen for PCOS, which shares an insulin-resistant mechanism with skin tag formation.

Which risk category fits you: a decision framework

Not every skin tag warrants a full endocrine workup, and not every clinician draws the line in the same place. The categories below are a practical synthesis built from the case-control literature and ADA glucose/HbA1c criteria. They are not a verbatim guideline and should not replace a clinician's judgment about your specific history.

The tradeoff to understand: removing a skin tag treats the visible symptom, not the driver. A patient who has five tags removed but never gets a fasting insulin drawn has addressed nothing about their diabetes risk. Conversely, a patient with one or two tags and no other risk factors does not need an endocrine workup just because skin tags are "linked to diabetes" in general.

Other conditions linked to skin tags

Metabolic syndrome. Defined by three or more of: waist circumference above 102 cm (men) or 88 cm (women), triglycerides above 150 mg/dL, HDL below 40 mg/dL (men) or 50 mg/dL (women), blood pressure above 130/85, and fasting glucose above 100 mg/dL. A case-control study by Sari and colleagues found a higher prevalence of metabolic syndrome in patients with skin tags than in age-matched controls Sari et al., 2010.

PCOS. Hyperandrogenism and insulin resistance drive skin tag formation in women with PCOS. Relevant labs include total and free testosterone, DHEA-S, SHBG, and an oral glucose tolerance test, evaluated against Rotterdam criteria.

Acromegaly. Rare, but worth knowing about. Excess growth hormone stimulates fibroblast proliferation directly. Look for coarsening facial features, enlarged hands and feet, and diffuse skin tags. An IGF-1 level screens for this per Endocrine Society guidance Katznelson et al., 2014.

Pregnancy. Estrogen and progesterone shifts, combined with weight gain and skin friction, produce new skin tags in a meaningful share of pregnancies. These commonly regress postpartum and typically do not need metabolic workup unless other risk factors are present.

Crohn's disease. An older surgical case series found perianal skin tags in roughly a quarter of the Crohn's patients it studied, describing them as a marker of disease activity distinct from ordinary friction-zone acrochordons Keighley & Allan, 1986. That figure comes from a small, dated surgical cohort and should be treated as a directional signal, not a precise modern prevalence estimate. Perianal tags accompanied by pain, fissures, bleeding, or altered bowel habits warrant gastroenterology referral regardless of the exact percentage.

When does a skin tag need more than reassurance?

Most skin tags need nothing beyond a primary care visit for lab screening and, if desired, removal. Certain features change that.

See a dermatologist if a growth changes color, bleeds without trauma, grows rapidly, or has an irregular base. These are not features of a typical acrochordon and can indicate a different diagnosis, including seborrheic keratosis, neurofibroma, or, rarely, amelanotic melanoma. A shave biopsy is quick and gives a definitive answer.

See an endocrinology-capable clinician if labs show HbA1c above 6.0%, a HOMA-IR notably elevated for your lab's reference range, or criteria for metabolic syndrome. These findings call for structured management, not just general advice to eat better and move more.

See a gastroenterologist if skin tags cluster around the perianal area and you have chronic diarrhea, abdominal pain, rectal bleeding, or unintentional weight loss. Isolated perianal tags can be benign; the combination with GI symptoms is what changes the picture.

Removal options and what to expect

Removal is almost always classified as cosmetic unless a tag is symptomatic (repeated bleeding, pain from friction, or, for eyelid tags, interference with vision). Coverage decisions vary by insurer and by documentation of symptoms, so confirm your specific plan's policy before scheduling, and ask your provider for a cost estimate in advance rather than relying on a general figure.

Snip excision. The clinician numbs the base, lifts the tag with forceps, and cuts the stalk. Healing typically takes about a week. Common for tags 2 mm or larger.

Cryotherapy. Liquid nitrogen freezes the tag, which blisters and falls off over one to two weeks. Useful for small or numerous tags treated in one session.

Electrodesiccation. Fine-tip cautery destroys the tag at its base with minimal bleeding, useful for larger pedunculated tags.

Home ligation with thread, floss, or rubber bands is not recommended; incomplete ligation can cause infection or scarring. Over-the-counter freezing kits reach far colder temperatures than home methods but still do not match the temperature clinical liquid nitrogen achieves, so they tend to be less reliable.

Does treating insulin resistance reduce new skin tags?

Because insulin resistance is the leading mechanistic driver for people with multiple skin tags, it is biologically plausible that treatments which lower circulating insulin would slow new tag formation. That plausibility is mechanistic, not directly tested.

In the STEP 1 trial, participants on semaglutide 2.4 mg weekly lost substantially more body weight than those on placebo over 68 weeks Wilding et al., 2021. The SCALE substudy found that liraglutide 3.0 mg improved HOMA-IR over 56 weeks compared with placebo Pi-Sunyer et al., 2015. Weight loss of that magnitude is expected to reduce insulin resistance generally.

No randomized trial has measured skin tag recurrence or new tag formation as a primary or secondary endpoint. This is a genuine evidence gap, not a minor caveat. Any statement that GLP-1 therapy "reduces skin tags" goes beyond what the trial evidence supports; the honest statement is that these drugs improve the metabolic driver that is associated with skin tag formation, and clinical observation of fewer new tags in patients whose insulin sensitivity improves is plausible but unproven.

Metformin remains a commonly used first-line insulin sensitizer for patients who are not candidates for GLP-1 therapy. The Diabetes Prevention Program trial found that metformin reduced diabetes incidence compared with placebo over 2.8 years, with lifestyle intervention performing even better Knowler et al., 2002. Specific dosing and titration should be individualized by a clinician based on kidney function, tolerability, and other medications, not taken from a general article.

The 2016 AACE/ACE clinical practice guideline on obesity states that pharmacologic therapy is appropriate for patients with a BMI of 27 kg/m² or higher who also have at least one weight-related comorbidity, a category that can include insulin resistance Garvey et al., 2016. This is a guideline threshold for obesity pharmacotherapy in general; it is not a claim that any specific drug reduces skin tags.

What's established, what's plausible, and what isn't

Established: Skin tags are benign with no malignant potential. Multiple case-control studies show an association between skin tag clusters and elevated fasting insulin, HOMA-IR, and an atherogenic lipid pattern, independent of BMI. ADA guidance supports considering metabolic screening when dermatologic findings like skin tags or acanthosis nigricans are present.

Plausible but unproven: That improving insulin sensitivity through weight loss, metformin, or GLP-1 therapy reduces the rate of new skin tag formation. The mechanism is coherent, but no trial has tested it directly.

Not established: Any specific tag-count threshold (such as "five or more") as an official diagnostic trigger; ADA guidance recommends considering screening based on dermatologic findings generally, without a codified number. Also not established: that removing existing skin tags affects metabolic risk in any direction, or that skin tags predict cardiovascular events beyond what their associated lipid and glucose abnormalities already indicate.

A practical sequence of steps

First, count and map your skin tags. Note location, size, and whether any have changed recently, and photograph them to track change over time.

Second, schedule a primary care visit and request fasting glucose, HbA1c, fasting insulin (for HOMA-IR), and a lipid panel. Add testosterone, DHEA-S, and SHBG if you have irregular periods or hirsutism.

Third, if labs show prediabetes or an elevated HOMA-IR, start lifestyle changes: the DPP trial supports roughly 150 minutes per week of moderate activity and a 5 to 7% body weight loss goal as an effective, well-studied intervention Knowler et al., 2002.

Fourth, if lifestyle change alone is insufficient after several months, or your baseline risk is high, discuss pharmacotherapy options with your clinician. Whether metformin, a GLP-1 receptor agonist, or another approach fits depends on your BMI, comorbidities, and preferences, and should be decided individually rather than from a general guide.

Fifth, remove bothersome tags at your clinician's discretion. This addresses the least medically important part of the picture but is often what motivates people to seek care in the first place. New tags can keep appearing if the underlying metabolic driver is not addressed.

Recheck labs a few months after starting treatment. A falling HOMA-IR and HbA1c are the signal that the metabolic picture is improving; whether new skin tag formation slows alongside that improvement is worth tracking, but is not itself a validated clinical endpoint.